IL-36, LCN2, leukotriene A4-hydrolase (LTA4H), MMPs, S100A proteins, G-CSF receptor, and CXC receptors are just some of the possible therapeutic targets for future treatment of HS [153,154]. Here, LCN2 is linked to histiocytic sarcoma.